Collectively, our results indicate that Yap plays critical roles in T cell biology, and suggest that inhibiting Yap activity improves T cell responses in cancer.
INTRODUCTION

CD8
+ and CD4 + T cells are central players in the adaptive immune system. T cells elicit targeted,
antigen-specific responses for direct killing of an infected or transformed cell, shaping and regulating the immune response in host defense [1] . Most mature T cells circulate in a resting, naïve state, and upon cognate antigen recognition, T cells become activated, proliferate clonally, and differentiate into effector T cells. Naïve CD8 + T cells differentiate into cytotoxic T cells, while CD4 + T cells differentiate into an array of different types of helper T cells (i.e., Th1, Th2, Th17 or Treg) depending on microenvironmental cues [2] . Each phenotype is defined by expression of signature transcription factors and effector cytokines leading to distinct functions [3] .
T cell activation also upregulates negative feedback mechanisms, such as inhibitory receptors, which restrain their action to minimize pathogenic inflammation and autoimmunity [1, 4] . This network of immunosuppressive factors is frequently co-opted in chronic infections and cancer, leading to terminally differentiated and exhausted T cells that lose effector function and ability to infiltrate disease sites [5] . The finding that revitalization of exhausted, dysfunctional T cells can restore the immune response has revolutionized cancer therapy with the use of checkpoint inhibition [6] . Chimeric antigen receptor T cells (CAR-T), engineered for enhanced antigen recognition and co-stimulation also demonstrate promising clinical efficacy [7] [8] [9] . However, both immunotherapies are effective for only a fraction of patients [10] [11] [12] [13] [14] . Major challenges to extending the efficacy of immunotherapy to more cancer patients include sustaining T cell activation and achieving T cell infiltration in the immunosuppressive microenvironment of solid tumors [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Improved understanding of mechanisms controlling T cell differentiation and function is critical to overcoming these barriers.
Yap is a key effector of the Hippo signaling pathway, directing transcriptional programs that control stem cell biology by integrating microenvironmental and cell intrinsic cues [25] . Yap regulation leads to control of cell death and survival, proliferation and cell fate determination, and dysregulated Yap activity contributes to disease, most notably cancer [26] . While the dynamics of Yap regulation coupled with differentiation are well characterized in stem cells and tissue specific progenitor cells, less is known about the role of Yap in T cells. The Hippo pathway has been implicated in coupling CD8 + T cell clonal expansion to terminal differentiation through upregulation of kinase LATS1 and Yap degradation [27] . The Hippo pathway kinases MST1/2 have also been implicated in thymocyte egress and antigen recognition, lymphocyte polarization, adhesion and trafficking, survival, differentiation and proliferation [28] [29] [30] [31] [32] [33] [34] [35] [36] . Further, an immunecell intrinsic role for Yap in CD4 + T cells has also been described, with Yap being shown to be critical for potentiating TGFβ/SMAD signaling responses that direct Treg function [37] . In this study, the conditional deletion of the Yap gene using CD4-Cre or Foxp3-Cre models was shown to lead to reduced tumor growth in syngeneic mouse models of cancer, with Yap being linked mechanistically to Treg function and stability in vitro and in vivo [37] . However, the involvement of Yap in CD8 + T cells and other CD4 + subtypes has remained understudied.
In this study, we sought to determine whether Yap has overlapping control over both CD4 + and CD8 + T cells and how these functions may affect cancer immunity. We observed that Yap expression is elevated upon T cell activation, and that conditional deletion of the Yap gene in CD4 + and CD8 + T cells using the CD4-Cre model leads to enhanced T-cell activation and differentiation.
These phenotypes translated to the reduced growth of B16F10 and LLC tumors in CD4Cre Yapdeleted mice, which showed strongly increased T cell tumor infiltration. Interestingly, using adoptive cell transfer experiments we observed that Yap-deleted CD8 + T cells have an intrinsic ability to infiltrate tumors with much higher efficiency, which is a major goal for improving cancer immunotherapy. RNA-sequencing analyses of Yap-deleted tumor infiltrated lymphocytes (TILs) revealed upregulation of key signaling pathways in T cell activation, differentiation and function in CD4 + and CD8 + T cells. Notably, we found that Yap regulated gene expression changes were tumor-specific, as we observed minimal gene expression changes in lymphocytes isolated tumordraining lymph nodes. Yap-regulated gene expression signatures from TILs correlated with T cell infiltration and patient survival across multiple human cancers in The Cancer Genome Atlas (TCGA), including melanoma and lung cancer, as demonstrated in our mouse studies. Our study merges new evidence with observations from prior studies, highlighting Yap as a broad suppressor of CD4 + and CD8 + T cell activation and function and a key regulator of T cell tumor infiltration and survival in cancer immunotherapy patients.
RESULTS
Yap inhibits CD4 + and CD8 + T cell activation
To study the role of Yap in T cells, we started by analyzing Yap levels in isolated primary CD4 + and CD8 + T cells from mice that were either unstimulated or activated with anti-CD3/CD28 coated beads for 24 hours. We observed that Yap RNA levels were dramatically increased upon stimulation of CD4 + and CD8 + T cells ( Figure 1A-B Figure 1A- 
B).
We next measured the surface levels of activation markers (CD69 and CD25) in Yap-cKO T cells.
CD4
+ and CD8 + T cells were isolated from wild type (WT) and Yap-cKO mouse spleens, activated, and levels of CD69 and CD25 were measured 24 hours later. We found increased levels of CD25 (Figure 2A-C) . These observations were distinct from prior findings that suggested Treg-specific functions for Yap [37] , and implicate Yap as a broad inhibitor of CD4 + T cell activation and differentiation.
Deletion of Yap in T cells promotes T cell infiltration into developing tumors and blocks tumor growth
Since we observed that Yap inhibits T cell activation and differentiation in vitro, we aimed to study the effect of Yap deletion in vivo. We started by examining the growth of the subcutaneous B16F10 mouse tumor model in Yap-cKO mice, due to the poor immunogenic phenotype and highly immunosuppressive microenvironment that leads to low T cell infiltration in this model [41] [42] [43] [44] . Yap deletion in T cells resulted in superior anti-tumor immunity, as evidenced by the significant delay in tumor growth in Yap-cKO compared to WT mice ( Figure 3A-B) , consistent with prior observations [37] . The growth of subcutaneous Lewis lung carcinoma (LLC) tumors was also significantly reduced in Yap-cKO mice ( Figure 3C-D 
3F-H).
To directly address whether Yap-deleted T cells have an increased ability for tumor infiltration we isolated CD8 + T cells from Yap-cKO and WT mice and directly compared them in adoptive transfer experiments in WT mice challenged with B16F10 tumor cells (illustrated in Figure 3I ). Previous studies have demonstrated proliferation has a sharp, switch-like threshold for T cell receptor signal to elicit proliferation [57] , and our experimental conditions provide optimal signaling above this threshold. Expression levels of activation markers have been directly linked to TCR signal strength, such as CD69 levels being directly regulated by affinity and dose of TCR ligand [58] and CD71 levels being directly linked to mTOR activation level [59] . Our observations therefore support a novel conceptual advance: that Yap may link TCR signal strength to negative feedback.
The rapid induction of Yap post-activation suggests that there are no Yap-specific inducers in the tumor, but rather that the signals driving Yap expression are shared canonical signals of T cell activation. These observations are consistent with those made previously by Thaventhiran et al.
[27], but contrast a Treg specific role proposed by Ni et al [37] . Our data suggest that Yap promotes a normal negative feedback mechanism during T cell activation similar to inhibitory checkpoint molecules, and inhibition of Yap must be timed before or during T cell activation. Regulation of T cell activation by the microenvironment through polarizing cytokines allows for diverse, context-specific differentiation and functional diversity in CD4 + T cells [3] . We observe Yap include several key effectors of T cell activation, including those controlling JAK-STAT signaling that modulate the polarization of naïve CD4s into T helper subsets [60] . Notably, Yapregulated genes are also enriched for those regulated by the TGFb and Wnt pathways, which have important pleotropic roles in T cell biology [61, 62] . Given the known convergence of Yap with these immunomodulatory pathways [63] it is likely Yap directs their transcriptional targets and signal strength. Our study provides novel evidence of CD4 + and CD8 + T cell-intrinsic effects of Yap on T cell activation and tumor infiltration. 
MATERIALS & METHODS
Mouse Strains and Genotyping
Yap-loxP/loxP mice provided by Dr. Jeff Wrana and previously described [68] were backcrossed to the C57BL/6 background for 10 generations, and bred with the Tg(Cd4-cre)1Cwi (Jax: 022071)
[69] and LSL-EYFP (Jax: 006148) [70] lines to derive Yap-loxP/loxP; LSL-EYFP; CD4-Cre mice.
For adoptive cell transfers, CD4-cre mice were crossed with LSL-tdTomato mice (Jax: 007914) [71] . All experiments were performed with 6-10 weeks old mice. Animal protocols and study designs were approved by Boston University School of Medicine and UMBC. Mice were maintained in pathogen-free facilities at BUMC and UMBC and were PCR genotyped using published protocols [68] [69] [70] [71] .
Cell culture and mouse tumor challenges 
T cell isolation
Spleens from WT or YAP-cKO mice were pushed through a 70µm mesh (Falcon) using an insulin syringe plunger and washed with PBS. Cells were treated with ACK red blood cell lysis buffer and splenocyte single cell suspensions were prepared for magnetic separation or stained for sorting by flow cytometry. CD4 + or CD8 + T cell enrichment was performed using magnetic beads (Miltenyi Biotec or STEMCELL Technologies). Naïve CD4 + T cells were isolated using a naive CD4 + T cell isolation kit (Miltenyi Biotec). 
Adoptive cell transfers
T cell activation and proliferation assays
CD4 + or CD8 + T cells were isolated using magnetic beads as described above. Cells were stained using the CellTrace Violet or CFSE Cell Proliferation Kit (Life Technologies). Briefly, purified cells were washed with PBS and incubated with CellTrace dye for 20 minutes at 37°C
protected from light. After 20 minutes, complete RMPI medium was added to the cell suspension and the cells were incubated 5 minutes further before being washed and resuspended in complete RPMI medium. Cells were cultured in 96 well plates at 1x10 5 cells per well and were stimulated using aCD3/CD28 dynabeads (Gibco) at a 1:1 ratio with T cells. On days 1 and 3, cells were stained with dead cell dye as well as lineage and activation markers CD3, CD4, CD8, CD69, CD71, and CD25 and proliferation was measured at the same time.
CD4 + T cell in vitro differentiation
For CD4 + T cell in vitro differentiations into Th1, Th2 and Th17 subsets, naïve CD4 + T cells were enriched using magnetic beads (Miltenyi Biotec). Purified cells were plated at 1x10 5 cells per well on a 96 well plate coated with 10µg/ml aCD3 (Biolegend), and cultured with 2µg/ml soluble aCD28 (Biolegend). The following conditions were specific to each differentiation regime: Th1, 10ng/ml IL-12 and 10µg/ml aIL-4; Th2, 50ng/ml IL-4, 10µg/ml aIFNg and 10µg/ml aIL-12;
Th17, 50ng/ml IL-6, 20ng/ml IL-1b, 5ng/ml IL-23, 1ng/ml TGFb, 12µg/ml aIFNg and 10µg/ml aIL-4. Cells were cultured for 5 days, before being stimulated with 50ng/ml PMA (Sigma, P1585) and 1µg/ml ionomycin (Sigma, I0634) for 6 hours at 37 °C in the presence of Golgistop (monensin, BD) or Golgiplug (brefeldin, BD) added after the first 30 minutes of stimulation. Cells were stained with dead cell dye, surface markers (CD3, CD4, CD8, CD25) and intracellular cytokines (IFNg, IL-17) or transcription factors (GATA3) as described above.
Immunofluorescence microscopy
Harvested B16 tumors were fixed overnight in PLP fixative, followed by incubation in 15% and 30% sucrose. Tumors were embedded in OCT and frozen. Cryosections were cut at 5µm thickness and stored at -20°C. On the day of staining, slides were air dried for 1 hour and fixed in acetone for 10 minutes. Slides were washed with PBS and blocked with PBS containing 10% donkey serum, 0.05% sodium azide, 0.5% triton X-100 and 0.2% BSA for 1 hour at room temperature. Slides were stained with rat anti-mouse CD8 (clone CT-CD8a, Fisher) for 2 hours at room temperature, and were subsequently washed with PBS containing 1%
Tween. Secondary antibody was diluted in blocking buffer and applied for 1 hour at room temperature (donkey anti-rat alexa 647, Jackson Immuno Research Labs). Slides were washed and mounted in ProLong antifade reagent with DAPI (Life Technologies). Images were acquired using an AxioObserver D1 equipped with a X-Cite 120LED System.
Quantitative real-time PCR (qPCR)
RNA was extracted using Rneasy Mini Kit (Qiagen), and 1µg was used to generate cDNA using an iScript cDNA Synthesis Kit (Biorad). Taqman primers for mouse GAPDH and YAP (Life Tech) were mixed with cDNA and Taqman Universal Master Mix II (Life Tech) and CT values were normalized to unstimulated controls.
Sample preparation for RNA-Seq
B16 tumors from WT and YAP-cKO mice were digested as described above. Tumors were subsequently stained with dead cell dye and antibodies against CD45, CD3, CD4, and CD8, and CD4 + and CD8 + TILs were sorted from each tumor using a BDFACSARIA instrument. CD4 + and CD8 + T cells were sorted from WT and YAP-cKO tumor draining lymph nodes, as well. Cells were sorted into TRIzol LS reagent (Invitrogen) and RNA was isolated using a miRNeasy micro kit (Qiagen).
Transcriptomic analyses and gene expression signature extraction
RNA quality was evaluated using Agilent Bioanalyzer 2100 Eukaryote Total RNA Pico chips.
RNA-Seq libraries were prepared using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara, 634889) from total RNA, following the manufacturer's protocol. Libraries were then sequenced on a HiSeq 4000 using 75-bp paired end reads to an average depth of 22,445,650 ± 240,398 reads (SEM). Transcript abundance estimates were quantified using Salmon to mouse reference transcriptome from assembly GRCm38 (mm10), aggregated to gene level for UCSC-annotated genes using tximport, and DESeq2 was used to calculate normalized counts and differential expression [72, 73] . CD4 and CD8 up/down gene signatures were generated through differential expression analysis via DESeq2. Differentially expressed genes (DEG) between CD4 vs. WT and were generated using the ComplexHeatmap software package available in R.
Analysis of gene expression signatures in TCGA datasets
The activation of CD4/8 up/down signatures was calculated with Gene Set Variation Analysis (GSVA) [74] in primary tumor samples across multiple TCGA RNA-Seq datasets. For each data set, Kaplan-Meier survival plots were generated and the results were summarized with a heatmap. The color of each cell corresponds to the following categories. Dark blue in the graphs signifies the average survival probability for patients with low activity of the signature is higher while red signifies the average survival probability for patients with high activity of the signature is higher. Light blue and light orange signify the same groups with higher survival probability respectively, however the difference is not significant. The text of each cell is the pvalue for the survival estimation. The distribution of p-values arising from the multiple survival analyses for each signature across TCGA datasets was compared to a uniform distribution using a Kolmogorov-Smirnov test. 
